A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Glaxo Wellcome
• Treatments: Zidovudine

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Concurrent Medication:

Excluded:

• Other anti-retroviral agents.

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Patients must be:

• HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.

• At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).

• Also patient must fall into one of the following categories:

• Have an HIV seronegative identical twin to serve as a bone marrow donor.

• Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.

• Be a good risk candidate for bone marrow transplant.